Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMPL-453 in Advanced Malignant Mesothelioma
NCT04290325Phase 2Unknown
- Sponsor
- Hutchison MediPharma (HMP)
- Start
- Dec 2019
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fanregratinib in malignant mesothelioma, sponsored by Hutchison MediPharma (HMP). Status: unknown.
02
Drugs
fanregratinib
03
Conditions
malignant mesothelioma
Beyond the preview
Go deeper on NCT04290325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04290325.